"No [Right] Way to be a Black Woman": Exploring Gendered Racial Socialization Among Black Women.

Using the theoretical lenses of intersectionality and racial-ethnic socialization, we conducted a focus group study with 29 Black women. We analyzed transcripts for the sources of messages about skin color and hair and for participants' responses to these messages via a grounded theory approach. Family members were the primary source of messages about skin color and hair. Peers and the media also communicated such messages. Messages ranged from endorsement of Western standards of beauty to an embrace of darker skin colors and natural hair texture. Rather than serving as passive recipients of messages, participants sifted through and reconciled messages with varying degrees of resolution. Their accounts reflected their intersectional experiences as Black women, representing a variety of physical attributes. We discuss the influence of these physical attributes on their individual racial-gender identity development in light of a second burgeoning Black hair movement that embraces Black natural hair in the U.S. Findings may help families and others build understanding of and increase sensitivity towards the intra- and interpersonal implications of colorism for Black women. Findings may also inform institutional policies (e.g., school, work) and practices such that they no longer create barriers or yield consequences for the Black women navigating these settings.

Treatment of idiopathic immune-mediated hemolytic anemia with mycophenolate mofetil in five dogs.

BACKGROUND: The optimal treatment for immune-mediated hemolytic anemia (IMHA) in dogs remains unknown. Mycophenolate mofetil (MMF) is being used with increasing frequency in veterinary medicine for immune-mediated diseases. The goal of this pilot study was to evaluate a series of dogs diagnosed with idiopathic IMHA treated with MMF and other standard therapies. Study endpoints included all cause mortality, hospitalization length, time to resolution of spherocytosis and anemia, time to discontinuation of medications, transfusion requirement, relapse events, and MMF-induced adverse events. KEY FINDINGS: Five dogs diagnosed with idiopathic IMHA received prednisone, MMF, and low-dose aspirin, along with transfusions and supportive therapies as indicated. One dog was euthanized on day 20 for progressive IMHA. One dog was euthanized on day 115 for intolerable MMF-induced gastrointestinal (GI) toxicity. Three dogs survived >1 year beyond the initial diagnosis and are alive at the time of this writing. The median length of hospitalization was 48 hours. The median time to resolution of the spherocytosis and anemia was 13 days and 44 days, respectively. The overall median time to discontinuation of MMF was 165 days. Two dogs required the use of modified cyclosporine (one with MMF, one without MMF). All dogs had suspected MMF-induced GI toxicity, including vomiting, anorexia, or diarrhea; in 2 dogs, these side effects necessitated discontinuation of the MMF. SIGNIFICANCE: Although the study demonstrated a potential use of MMF in the induction of remission of IMHA in 4 out of 5 dogs evaluated, the level of significant MMF-induced GI toxicity cannot justify its use with the dosage regime described here.

Verification of dioxin formation in a catalytic oxidizer.

Emissions and inlet concentrations of polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDD/PCDF) have been measured from a catalytic oxidizer and a thermal oxidizer. The catalyst inlet temperature was 427 degrees C. The thermal oxidizer operating temperature was 791 degrees C. Data of the toxic dioxin and furan congeners are reported. Important results of this field study are: (1) the catalytic oxidizer in this study produced an increase in PCDD/PCDF congener concentration of almost 10-fold from the inlet to the outlet (stack), thus verifying results of a previous study that evaluated only PCDD/PCDF emissions. All congeners increased from inlet to the stack. (2) The thermal oxidizer had little effect on PCDD/PCDF levels. There was a decrease in four of the congeners and an increase in 13 congeners. (3) Ambient air was the main source of PCDD/PCDFs in the stack emissions of the thermal oxidizer in this study. Laboratory investigations are needed to understand how PCDD/PCDFs are formed (and emitted) under conditions of this study.

Efficacy and safety of a purified porcine insulin zinc suspension for managing diabetes mellitus in dogs.

The objective of this study was to evaluate the safety and efficacy of a purified porcine insulin zinc suspension for treating dogs with uncomplicated diabetes mellitus. Fifty-three dogs were treated for 60 days after an initial dose determination period. The means of the blood glucose concentrations during 12-hour glucose curves and the means of the blood glucose nadir concentrations during 12-hour glucose curves for all dogs were determined before beginning insulin therapy (time 0), at the end of the dose determination period (time 1), 30 days after time 1 (time 2), and 60 days after time 1 (time 3). Presence of polyuria, polydipsia, and ketonuria was determined at each time point. Adequacy of control of hyperglycemia was based on 12-hour blood glucose curves and improvement in clinical variables (results of physical examinations, historic information, polyuria, polydipsia, and ketonuria). Safety was evaluated by questionnaire, performance of physical examination, CBC, serum chemistry profile, and urinalysis. The means of the blood glucose concentrations during 12-hour glucose curves and the means of the blood glucose nadir concentrations during 12-hour glucose curves for all dogs at times 1, 2, and 3 were significantly lower compared with time 0 (P < .0001). There was a reduction in the proportion of dogs with polyuria, polydipsia, and ketonuria of 82, 86, and 80%, respectively. All of the dogs had adequate glycemic control at time 1, 66% at time 2, and 75% at time 3. At time 3, 66% of dogs required insulin injections q12h. Other than hypoglycemia, there were no important adverse effects of insulin administration. The insulin, was safe and efficacious for reducing blood glucose and clinical signs in dogs with diabetes mellitus.

Emissions of polychlorinated dibenzo-p-dioxins and dibenzofurans from catalytic and thermal oxidizers burning dilute chlorinated vapors.

Emissions of polychlorinated dibenzo-p-dioxins and dibenzofurans (dioxins) have been found from 57 field tests on the oxidation of low (a few to a few hundred) parts per million levels of chlorinated and non-chlorinated volatile organic compounds (VOCs). The oxidation occurs in catalytic oxidizers with platinum, platinum/palladium or chromium(IV) oxide combustion catalysts, or in thermal oxidizers (without a catalyst). The catalyst inlet temperatures ranged from 293 to 573 degrees C. The thermal oxidizer operating temperatures (post-flame) were from 773 to 927 degrees C. Data of the toxic dioxin and furan isomers are reported and also weighted and expressed as international toxic equivalents (TEQ) of 2,3,7,8-tetrachlorodibenzo-p-dioxin. The maximum stack emissions, 1.07 ng/m3 TEQ, occurred at 293 degrees C. Salient results of this field study are: (1) TEQ levels in the stack exponentially increase with a decrease in operating temperature, an empirical equation is TEQ (ng/dscm)=8.4 exp(-0.0084T degrees C); (2) dioxin/furan production occurs at the combustion catalyst; (3) small variations in temperature cause large changes in the congener distribution of the dioxin and furan isomers; (4) molar TEQ yields from the parent compounds fed to the oxidizers are very small (10(-9)-10(-13)); (5) catalytic and thermal oxidizers may destroy dioxins fed from the ambient air; and (6) the oxidation of chlorinated VOCs with non-chlorinated VOCs reduces emissions of dioxins, likely due to the consumption of Cl in producing HCl. Laboratory investigations are needed to understand how dioxins are formed (and emitted) under conditions of this study.